Hunan Fangsheng Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Hunan Fangsheng Pharmaceutical has a total shareholder equity of CN¥1.7B and total debt of CN¥688.6M, which brings its debt-to-equity ratio to 40.2%. Its total assets and total liabilities are CN¥3.3B and CN¥1.6B respectively. Hunan Fangsheng Pharmaceutical's EBIT is CN¥193.3M making its interest coverage ratio -6.8. It has cash and short-term investments of CN¥212.0M.
Key information
40.2%
Debt to equity ratio
CN¥688.60m
Debt
| Interest coverage ratio | -6.8x |
| Cash | CN¥211.97m |
| Equity | CN¥1.71b |
| Total liabilities | CN¥1.57b |
| Total assets | CN¥3.29b |
Recent financial health updates
No updates
Recent updates
Hunan Fangsheng Pharmaceutical's (SHSE:603998) Earnings Are Weaker Than They Seem
Nov 04
The Market Doesn't Like What It Sees From Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Earnings Yet
Jun 06Earnings Troubles May Signal Larger Issues for Hunan Fangsheng Pharmaceutical (SHSE:603998) Shareholders
Apr 30Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) 34% Share Price Surge Not Quite Adding Up
Mar 04Financial Position Analysis
Short Term Liabilities: 603998's short term assets (CN¥1.0B) do not cover its short term liabilities (CN¥1.4B).
Long Term Liabilities: 603998's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥179.9M).
Debt to Equity History and Analysis
Debt Level: 603998's net debt to equity ratio (27.9%) is considered satisfactory.
Reducing Debt: 603998's debt to equity ratio has increased from 25.3% to 40.2% over the past 5 years.
Debt Coverage: 603998's debt is well covered by operating cash flow (31.4%).
Interest Coverage: 603998 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 17:35 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Fangsheng Pharmaceutical Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wentao Li | Citic Securities Co., Ltd. |
| Kehan Meng | Haitong International Research Limited |
| Wenxin Yu | Haitong International Research Limited |